Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets from th
May 16, 2012: Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets from the U.S. FDA

Glenmark Generics receives U.S. FDA approval for Lamotrigine Tablets
May 7, 2012: Glenmark Generics receives U.S. FDA approval for Lamotrigine Tablets

Glenmark Generics receives ANDA approval for Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg
Apr 9, 2012: Glenmark Generics receives ANDA approval for Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg

Glenmark Generics receives ANDA approval for Desogestrel & Ethinyl Estradiol Tablets
Apr 3, 2012 : Glenmark Generics receives ANDA approval for Desogestrel & Ethinyl Estradiol Tablets

Glenmark Generics receives USFDA approval for Imiquimod Cream
Mar 7, 2012 : Glenmark Generics receives USFDA approval for Imiquimod Cream

Glenmark Generics receives ANDA approvals for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estr
Mar 1, 2012 : Glenmark Generics receives ANDA approvals for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg

Glenmark Generics Inc. Announces
Feb 24, 2012 : Glenmark Generics Inc. Announces

Glenmark Generics receives Two Oral Contraceptives product approval from the USFDA
Jan 20, 2012 : Glenmark Generics receives Two Oral Contraceptives product approval from the USFDA

Glenmark Generics gets Tentative Approval for Montelukast Sodium 10 mg tablets from the USFDA
Nov 28, 2011: Glenmark Generics gets Tentative Approval for Montelukast Sodium 10 mg tablets from the USFDA

Glenmark wins Two Prestigious Global Recognitions at SCRIP Awards 2011
Glenmark wins Two Prestigious Global Recognitions at SCRIP Awards 2011

Glenmark confirms settlement for Hydrocortisone Butyrate
Glenmark confirms settlement for Hydrocortisone Butyrate

Glenmark Confirms Settlement of Litigation with Nycomed
Glenmark Confirms Settlement of Litigation with Nycomed

Glenmark Generics receives final approval from USFDA for Fluticasone propionate 0.05% lotion
Glenmark Generics receives final approval from USFDA for Fluticasone propionate 0.05% lotion

Glenmark Generics receives final approval from USFDA for Norethindrone and Ethinyl Estradiol
Glenmark Generics receives final approval from USFDA for Norethindrone and Ethinyl Estradiol, USP 0.4 mg/0.035 mg tablets

Glenmark Generics receives final approval from the U.S. FDA for Levocetirizine Dihydrochloride
Glenmark Generics receives final approval from the U.S. FDA for Levocetirizine Dihydrochloride

Glenmark Generics receives final approval from the USFDA for Atovaquone and Proguanil hydrochloride
January 19, 2011: Glenmark Generics receives final approval from the USFDA for Atovaquone and Proguanil hydrochloride.

Glenmark Generics receives approval from the USFDA for Lithium Carbonate extended-release tablets
December 28, 2010: Glenmark Generics receives approval from the USFDA for Lithium Carbonate extended-release tablets

Glenmark Generics receives three ANDA approvals from the USFDA
December 23, 2010: Glenmark Generics receives three ANDA approvals from the USFDA. This includes tentative approval for Eszopiclone, the generic version of Sepracor’s Lunesta® which achieved annual sales of USD 760 million

Glenmark Generics receives approval from the USFDA for Felodipine
December 20, 2010. Glenmark Generics receives approval from the USFDA for Felodipine

Glenmark confirms patent infringement suit for Hydrocortisone Butyrate
November 8, 2010 : Glenmark confirms patent infringement suit for Hydrocortisone Butyrate

Glenmark Generics receives final approval for Pramipexole Dihydrochloride tablets
October 11, 2010 : Glenmark Generics receives final approval for Pramipexole Dihydrochloride tablets from the USFDA

Glenmark Generics receives approval from USFDA for Trospium tablets
August 16, 2010 Glenmark Generics receives approval from USFDA for Trospium tablets

Glenmark Generics receives approval from USFDA for Mometasone Furoate Topical Solution USP, 0.1%
August 10, 2010 : Glenmark Generics receives approval from USFDA for Mometasone Furoate Topical Solution USP, 0.1%

Glenmark enters into a settlement and license agreement with Sepracor Inc to market generic Eszopicl
Aug 9, 2010 : Glenmark enters into a settlement and license agreement with Sepracor Inc to market generic Eszopiclone tablets

Glenmark Generics receives approval from the USFDA for Clotrimazole Cream USP, 1%
August 5, 2010: Glenmark Generics Inc., USA the subsidiary of Glenmark Generics Limited has received final ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Clotrimazole Cream USP, 1%

Glenmark Generics to launch Cyclobenzaprine Hydrochloride tablets in the US
July 30, 2010: Glenmark Generics Inc., USA (GGI), the United States subsidiary of Glenmark Generics Limited (GGL) has commenced marketing and distribution of Cyclobenzaprine Hydrochloride tablets in the U.S. market.

Glenmark Generics receives tentative approval from the USFDA for Riluzole 50 mg tablets
July 29, 2010: Glenmark Generics Inc., USA , the United States subsidiary of Glenmark Generics Ltd, announced today that the United States Food and Drug Administration (U.S. FDA) has granted tentative approval for Riluzole 50 mg tablets, the generic version of Rilutek® tablets by Sanofi Aventis US LLC.

Glenmark Generics receives tentative approval from the USFDA for Fluocinonide 0.1% cream
July 23, 2010 Glenmark Generics receives tentative approval from the USFDA for Fluocinonide 0.1% cream

Glenmark Generics receives approval from the USFDA for Norethindrone tablets 0.35mg - AB2
July 23, 2010 : Glenmark Generics receives approval from the USFDA for Norethindrone tablets 0.35mg This is Glemark’s third product approval for hormones and second approval for oral contraceptives

Glenmark Generics receives approval from the USFDA for Norethindrone Acetate tablets
July 22, 2010 : Glenmark Generics receives approval from the USFDA for Norethindrone Acetate tablets This is Glemark’s second product approval for hormones

Glenmark Generics receives approval from the USFDA for Theophylline extended-release tablets
July 14, 2010 : Glenmark Generics receives approval from the USFDA for Theophylline extended-release tablets

Glenmark Generics receives approval from the USFDA for Adapalene Gel
July 2, 2010: Glenmark Generics Inc., USA (GGI), a subsidiary of Glenmark Generics Limited (GGL), has received ANDA approval from the USFDA for Adapalene Gel, 0.1%.

Glenmark & Merck settle patent litigation covering Zetia®
May 11, 2010 : Glenmark & Merck settle patent litigation covering Zetia®

Glenmark Generics enters into an exclusive licensing agreement with Taro Pharmaceuticals, USA
May 6, 2010 : Glenmark Generics enters into an exclusive licensing agreement with Taro Pharmaceuticals, USA for a branded product

Glenmark Generics enters into an exclusive licensing agreement with Par Pharmaceuticals, USA
May 4, 2010 : Glenmark Generics enters into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe

Glenmark Generics receives USFDA approval for Norethindrone tablets
April 26, 2010 : Glenmark Generics receives USFDA approval for Norethindrone tablets 0.35mg. The product will be marketed under the trade name Heather®) and distribution is expected to start immediately

Glenmark Generics announces the settlement of Paragraph IV litigation with GSK
April 12, 2010 : Glenmark Generics announces the settlement of Paragraph IV litigation with GSK

Glenmark Europe receives UK-MA approval for Ropinirole Tablets & to distribute Lercanidipine HCL tab
April 7, 2010 : Glenmark Generics Europe receives UK-MA approval for Ropinirole film-coated tablets and to distribute Lercanidipine Hydrochloride film-coated tablets

Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride Tablets
April 1, 2010 : Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride Tablets

Glenmark Generics announces New Drug Applications for Oxycodone Hydrochloride Capsules & Liquid Soln
March 31, 2010 : Glenmark Generics announces New Drug Applications for Oxycodone Hydrochloride Capsules and Liquid Solution

Glenmark Generics receives approval from the USFDA for Calcipotriene Ointment
March 26, 2010: Glenmark Generics receives approval from the USFDA for Calcipotriene Ointment

Glenmark receives approval from USFDA for Moexipril Hydrochloride and Hydrochlorothiazide tablets
March 18, 2010 : Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride and Hydrochlorothiazide tablets

Glenmark Generics receives approval from the USFDA for Ropinirole Hydrochloride Tablets
March 2, 2010 : Glenmark Generics receives approval from the USFDA for Ropinirole Hydrochloride Tablets - Ropinirole Hydrochloride Tablets estimated market size at USD 104 million*

GGL granted tentative approval by US-FDA for Trandolapril & Verapamil Hydrochloride tablets
January 22, 2010 : Glenmark Generics Ltd granted tentative approval by US-FDA for Trandolapril and Verapamil Hydrochloride extended-release tablets • Glenmark believes that as of date it has sole first-to-file status on this product

Glenmark Generics Ltd receives Two Tentative Approval from USFDA
December 24, 2009 : Glenmark Generics Ltd receives Tentative Approval from USFDA for Pramipexole Dihydrochloride tablets and Atomoxetine Hydrochloride capsules

Glenmark Generics announces the settlement of Para IV litigations with Medicis Pharmaceutical Corpor
Nov 16, 2009 : Glenmark Generics announces the settlement of Para IV litigations with Medicis Pharmaceutical Corporation

Glenmark Generics receives ANDA approval from US-FDA for Ciclopirox Olamine Cream
Nov 14, 2009 : Glenmark Generics Limited (GGL) has received ANDA approval from the United States Food and Drug Administration for Ciclopirox Olamine Cream, 0.77 % and will commence marketing and distribution of this product in the U.S. market.

Glenmark Generics Europe announces the launch of its first Four Products for the UK market
October, 27, 2009 : Glenmark Generics (Europe) Ltd(GGEL), Glenmark Generics Limited’s (GGL) UK subsidiary has launched its first four products in the United Kingdom. This is the first time GGEL has launched products in its own livery in the UK. All these products will be sold directly by the UK subsidiary and through it’s own front end.

Glenmark Generics receives ANDA approval from the U.S. FDA for Verapamil SR tablets
September 18, 2009: Glenmark Generics receives ANDA approval from the U.S. FDA for Verapamil SR tablets

Glenmark Confirms Patent Challenge on Atovaquone & Proguanil Hydrochloride tablets
August 18, 2009: Glenmark Confirms Patent Challenge on Atovaquone & Proguanil Hydrochloride tablets

Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Ointment
July 31, 2009: Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Ointment

Glenmark to launch Fosinopril Sodium and Hydrochlorothiazide tablets in the US
July 10, 2009: Glenmark to launch Fosinopril Sodium and Hydrochlorothiazide tablets in the US

Glenmark Generics recieves ANDA approval from the U.S. FDA for Alclometasone Dipropionate Cream
June 25, 2009:Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Cream

Glenmark receives ANDA approval from U.S. FDA for Hydralazine Hydrochloride Tablets
June 01, 2009: Glenmark receives ANDA approval from U.S. FDA for Hydralazine Hydrochloride Tablets

Glenmark receives tentative approval from US-FDA for cholesterol-lowering agent Ezetimibe
April 27, 2009: Glenmark receives tentative approval from US-FDA for cholesterol-lowering agent Ezetimibe

Glenmark receives approval from the U.S. FDA for Lithium Carbonate Capsules
February 4, 2009: Glenmark receives approval from the U.S. FDA for Lithium Carbonate Capsules

Glenmark to market Levetiracetam tablets for the US market.
January 16, 2009: Glenmark to market Levetiracetam tablets for the US market.

Glenmark wins the Prestigious SCRIP awards 2008
December 11, 2008: SCRIP, the leading pharmaceutical magazine in the world Crowns Glenmark as the “Best Pharma Company in the World – SME” and the “Best Company in Emerging Markets” at the SCRIP Awards 2008 in London

Glenmark Confirms Patent Challenge of Fluticasone Lotion
Dec 17, 2008:Glenmark Confirms Patent Challenge of Fluticasone Lotion

Glenmark receives approval for Ranitidine Tablets USP from the U.S. FDA
Nov 21, 2008: Glenmark receives approval for Ranitidine Tablets USP from the U.S. FDA. - Ranitidine tablets are approved for eight separate indications

Glenmark Launches Azathioprine Tablets in the U.S. Market - Azathioprine is indicated as an adjunc
Nov 20, 2008:Glenmark Launches Azathioprine Tablets in the U.S. Market - Azathioprine is indicated as an adjunct for the prevention of rejection in kidney transplantation

Glenmark Generics Ltd enhances Pain Management Portfolio for the U.S Market
November 10, 2008: Glenmark Generics Ltd enhances Pain Management Portfolio for the U.S Market - Launches Morphine Sulfate Oral Solution

Glenmark Generics Limited launches its first product in the United Kingdom
Nov 06, 2008: Glenmark Generics Limited launches its first product in the United Kingdom - Launches Perindopril, an ACE inhibitor for symptomatic heart failure

Glenmark dermatology line expands with recent U.S. FDA approval
September 25, 2008:Glenmark dermatology line expands with recent U.S. FDA approval - Receives ANDA approval from U.S. FDA for Betamethasone Dipropionate Cream, 0.05% (Augmented) - Receives ANDA approval from U.S. FDA for Betamethasone Dipropionate Cream, 0.05% (Augmented)

Glenmark Generics launches Trandolapril Tablets
Mumbai, June 20, 2008: GGL has received ANDA approval from the US FDA for Trandolapril tablets USP 1 mg, 2 mg and 4 mg

Glenmark Generics receives three ANDA approvals
Mumbai, May 30, 2008: GGL has received ANDA approvals for Mometasone Furoate Ointment and Cream and Metformin Hydrochloride Tablets.

Glenmark implements Business Re-organisation
April 01, 2008: Glenmark announced that it has implemented the re-organization of its business into Specialty and Generics

Glenmark launches Clobetasol from its niche dermatology pipeline
March 17, 2008: Glenmark commences marketing and distribution of five Clobetasol Propionate dermatology products in the US market.

Glenmark launches Nabumetone and Hydroxyzine Tablets
March 13: Glenmark has initiated the marketing and distribution of Nabumetone tablets and Hydroxyzine Hydrochloride tablets in the U.S. market